||Researchers at the University
of Pennsylvania School of Medicine have discovered
a potential new target for treating type 2 diabetes.
||This study shows that when insulin is
present, as it is after a meal, the protein Akt2/PKB adds
a phosphate group to its molecular partner PGC-1a. When this
happens, PGC-1a cannot activate the genes needed for fat
||The findings suggest that if a drug could
induce Akt2/PKB to add the phosphate group (phosphorylation)
to PGC-1a, then the liver of a diabetic might be “fooled” into
stopping the oxidation of fat stores.
||This study appeared online this
week in Nature.
(PHILADELPHIA) – Researchers at the University
of Pennsylvania School of Medicine have discovered a potential new target for treating
2 diabetes, according to a new study that appeared online
this week in Nature. The target is a protein, along with its molecular
partner, that regulates fat metabolism.
“Over the last 10 years, we have begun to understand the importance
of fat metabolism in diabetes,” notes lead author Morris
J. Birnbaum, MD, PhD, the Willard and Rhoda Ware Professor of Diabetes and Metabolic
Diseases at Penn and an Investigator of the Howard
Hughes Medical Institute. “Type
2 diabetics are at a higher risk for cardiovascular
disease because they
also have disorders in fat metabolism as a result of obesity and abnormal
insulin action.” Birnbaum is also the Associate Director of the
Type 2 Diabetes
Unit for Penn’s Institute
for Diabetes, Obesity, and Metabolism.
When a person eats a meal, the pancreas usually responds by secreting
insulin that signals the liver to stop making glucose and burning fat.
When a type 2 diabetic eats a meal, insulin cannot stop the manufacture
of glucose in the liver, but it can stop the burning of fat stores. This
gives the diabetic person a “double whammy:” fatty acids
accumulate from food and from the liver. Consequently, more fat is deposited
in tissues and obesity worsens.
Until now there was no clear connection between insulin and the control
of fat metabolism. This study shows that when insulin is present, as
it is after a meal, the protein Akt2/PKB adds a phosphate group to its
molecular partner PGC-1a. When this happens, PGC-1a cannot activate the
genes needed for fat metabolism.
The findings suggest that if a drug could induce Akt2/PKB to add the
phosphate group (phosphorylation) to PGC-1a, then the liver of a diabetic
might be “fooled” into stopping the oxidation of fat stores. “Muscle
and fat tissue also burn fat stores, and we are currently investigating
whether PGC-1a and Akt2/PKB have the same role in those tissues,” says
The researchers also found that insulin-stimulated phosphorylation of
PGC-1a was blunted in mice that had non-functional Akt2/PKB. Finally,
they showed that livers with too much PGC-1a or with PGC-1a that could
not be phosphorylated put out many copies of the genes for fat metabolism.
Each approach pointed to the same conclusion: PGC-1a had phosphate groups
added to it by Akt2/PKB in the presence of insulin and this prevented
the turning on of genes that make fat.
There are currently no drugs that target PGC-1a and Akt2/PKB. “We
hope that drug companies will look for new ways to modify fat metabolism
in type 2 diabetics using these possible targets,” says Birnbaum.
Co-authors are first author Xinghai Li and Bobby Monks, both of Penn
and Qingyuan Ge of Cell Signaling
Technology, Inc. Dr. Birnbaum as an
Investigator of the Howard Hughes Medical Institute and receives additional
support for this work from the National
Institute of Diabetes and Digestive and Kidney Diseases.
PENN Medicine is a $2.9 billion enterprise
dedicated to the related missions of medical education, biomedical
research, and high-quality patient care. PENN Medicine consists
of the University of Pennsylvania School of Medicine (founded in
1765 as the nation's first medical school) and the University of
Pennsylvania Health System.
Penn's School of Medicine is ranked #2 in the nation for receipt
of NIH research funds; and ranked #3 in the nation in U.S. News
& World Report's most recent ranking of top research-oriented
medical schools. Supporting 1,400 fulltime faculty and 700 students,
the School of Medicine is recognized worldwide for its superior
education and training of the next generation of physician-scientists
and leaders of academic medicine.
The University of Pennsylvania Health System includes three hospitals,
all of which have received numerous national patient-care honors [Hospital
of the University of Pennsylvania; Pennsylvania Hospital, the nation's
first hospital; and Penn Presbyterian Medical Center]; a faculty practice
plan; a primary-care provider network; two multispecialty satellite
facilities; and home care and hospice.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.